MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--The long-term healthcare costs for patients suffering from a traumatic brain injury (TBI) with evidence of motor impairment are significantly higher than those of the general population, according to new research presented by SanBio, Inc., a scientific leader in regenerative medicine for neurological disorders. The findings from the study “Economic Burden of Illness for Patients with Traumatic Brain Injury Resulting in Chronic Motor Impairment,” were presented at the World Congress of Brain Injury in New Orleans on Friday, March 31.
Costs of TBI patients were highest during the acute phase of the injury. However, even in the second year post injury, TBI patients with evidence of motor impairment incurred excess costs of nearly $27,000 per patient. These costs appeared to stabilize at a rate of approximately four times higher than those of the control group costs.
Higher costs of TBI patients were associated with elevated use of all medical resources analyzed, including inpatient and outpatient services, emergency department visits, and physical therapy and rehabilitation services, as well as prescription drug use.
“Patients with traumatic brain injuries incurred significantly greater costs than the control group across the board for medical services,” said Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, and a study coauthor. “This study highlights the significant unmet need for effective care in this population, as well as the strain that this condition places on our entire healthcare system. There is a clear need for treatment that would help relieve the economic burden on patients suffering from the lingering effects of a traumatic brain injury.”
About the Study
The study, “The Economic Burden of Illness for Patients with Traumatic Brain Injury Resulting in Chronic Motor Impairment” was conducted by the Analysis Group, Inc., an economic and healthcare consulting firm, and funded by SanBio, Inc. The study examined the healthcare costs and resource utilization rates of 299 patients, age 18 to 75 years old, who were diagnosed with TBI in 2006 or later and had evidence of sustained motor impairment six months post injury. These patients were compared with a matched control group of nearly 600 patients without any record of brain injury. Healthcare costs and medical resource use were assessed for TBI patients and control groups over 6-month increments during the 24-month follow up period. Mean healthcare costs per patient in each 6-month period were calculated from the payer perspective, including medical services and prescription drug costs.
About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke. SanBio also began a Phase 2 clinical trial for treatment of motor impairment resulting from traumatic brain injury in late 2015. More information about SanBio, Inc. is available at http://san-bio.com.